Pharmaceuticals and brain health… biotech industry?
McDonald explains, “We are improving on first-generation psychedelic compounds like psilocybin. Unlike other products on the market, we are developing next-generation superior molecules that are engineered to target specific serotonin receptors. Our drugs will replace psilocybin in dealing with issues like depression. This leads to fewer side effects while improving safety and efficacy.”
Biotech companies can sometimes find the development of new products and drugs difficult, with various hurdles and lengthy trials slowing progress. However, due to advances already made and the urgency of the demand… psychedelic neuroscience companies [apparently] face less risk and can bring out products faster than others in the pharmaceutical field.
Original Article (International Business Times):
Pharmaceuticals and brain health: what’s the next step for the biotech industry?
Artwork Fair Use: Canadian Film Centre from Toronto, Canada
